Lantuejoul Sylvie, Damotte Diane, Hofman Véronique, Adam Julien
Département de Biopathologie, Centre Léon Bérard UNICANCER, Lyon, France.
Département de Recherche Translationnelle et d'Innovations, Centre Léon Bérard UNICANCER, Lyon, France.
J Thorac Dis. 2019 Jan;11(Suppl 1):S89-S101. doi: 10.21037/jtd.2018.12.103.
Lung cancer is the leading cause of cancer death worldwide with low response rates to conventional chemotherapy. New promising therapies have emerged based on programmed cell death protein 1 (PD-1) immunity checkpoint inhibitors (ICI), including anti-PD-1, such as nivolumab and pembrolizumab, or programmed death ligand 1 (PD-L1) inhibitors, such as atezolizumab, durvalumab, and avelumab. The prescription of pembrolizumab has been approved by FDA and EMA for advanced stages non-small cell lung carcinoma (NSCLC), restricted for first-line setting to patients whose tumor presents ≥50% of PD-L1 positive tumor cells (TC), and ≥1% for second-line and beyond, leading to consider PD-L1 assay as a companion diagnostic tool for pembrolizumab. Very recently, the EMA has approved durvalumab for the treatment of patients with unresectable stage III NSCLC not progressing after chemoradiotherapy and whose tumors express PD-L1 on ≥1% of TC. Four standardized PD-L1 immunohistochemistry assays have been used in clinical trials; 22C3 and 28-8 PharmDx assays on Dako/Agilent platforms, and SP142 and SP263 assays on Ventana platforms, each test having been developed initially for a specific ICI. They differ in terms of primary monoclonal antibody, platform, detection system and scoring methods with different thresholds of positivity validated in clinical trials. Several studies have shown a close analytical performance of the 22C3, 28-8 and SP263 assays regarding TC staining in NSCLC, with poor concordance with SP142 assay and for immune cells. However, as dedicated platforms are not available in all pathology laboratories and because of the high cost of these assays, laboratory developed tests are widely used in many countries. Their validation must guarantee the same sensitivities and specificities as compared to standardized assays. Overall, PD-L1 test is of great help to select patients who could benefit for ICI and most pathologists have included this test in their daily practice for advanced stages NSCLC, besides ALK and ROS1 IHC.
肺癌是全球癌症死亡的主要原因,对传统化疗的反应率较低。基于程序性细胞死亡蛋白1(PD-1)免疫检查点抑制剂(ICI)出现了一些有前景的新疗法,包括抗PD-1药物,如纳武单抗和派姆单抗,或程序性死亡配体1(PD-L1)抑制剂,如阿特珠单抗、度伐鲁单抗和阿维鲁单抗。派姆单抗已被美国食品药品监督管理局(FDA)和欧洲药品管理局(EMA)批准用于晚期非小细胞肺癌(NSCLC),一线治疗限于肿瘤中PD-L1阳性肿瘤细胞(TC)占≥50%的患者,二线及以后治疗限于肿瘤中PD-L1阳性肿瘤细胞占≥1%的患者,这使得PD-L1检测被视为派姆单抗的伴随诊断工具。最近,EMA已批准度伐鲁单抗用于治疗经放化疗后未进展且肿瘤中TC上PD-L1表达≥1%的不可切除III期NSCLC患者。四种标准化的PD-L1免疫组织化学检测方法已用于临床试验;Dako/安捷伦平台上的22C3和28-8 PharmDx检测方法,以及Ventana平台上的SP142和SP263检测方法,每种检测最初都是为特定的ICI开发的。它们在一抗、平台、检测系统和评分方法方面存在差异,在临床试验中验证的阳性阈值也不同。多项研究表明,22C3、28-8和SP263检测方法在NSCLC的TC染色方面具有相近的分析性能,与SP142检测方法以及免疫细胞检测的一致性较差。然而,由于并非所有病理实验室都有专用平台,且这些检测成本高昂,许多国家广泛使用实验室自行开发的检测方法。其验证必须保证与标准化检测方法具有相同的敏感性和特异性。总体而言,PD-L1检测对于选择可能从ICI中获益的患者有很大帮助,除了ALK和ROS1免疫组化检测外,大多数病理学家已将该检测纳入晚期NSCLC的日常实践中。